NeOnc secured IND clearance from Abu Dhabi’s Department of Health for its oral NEO212 bioconjugate, setting 610 mg as the Phase 2 dose and creating an international development pathway. Intranasal NEO100 Phase 2a trial for recurrent high-grade glioma is fully enrolled, with ~24% glioblastoma remission and interim data due 2026.
NeOnc received IND authorization from Abu Dhabi's Department of Health for its oral NEO212 bioconjugate following completion of Phase 1 dose escalation, which established 610 mg as the recommended Phase 2 dose and opens an additional clinical development pathway outside the US.
The intranasal NEO100 program achieved full enrollment in its Phase 2a study targeting recurrent IDH1-mutant high-grade glioma and related brain cancers, reporting tumor remission in approximately 24% of recurrent glioblastoma patients and anticipating interim and topline data later in 2026.
Chairman and CEO Amir Heshmatpour acquired more than $500,000 of open-market shares recently, bringing total insider purchases to nearly $1 million over the past year, reflecting management’s confidence as the company approaches key clinical and regulatory milestones.
NeOnc maintains financial flexibility through a $75 million at-the-market facility and a $10 million line of credit, while coverage by major financial institutions has increased, supporting funding for upcoming neuro-oncology catalysts and broader visibility among investors.
